The Saudi Journal of Medical Insights, Vol. 1, Page 88-96, December 2025

Synthetic Biology Approaches for Developing Probiotics: A New Era in Gut Health

Osman AE Elnoubi [1], Yahya Ahmed Aldashel [2], Mohammed Mahdi Ali Al-Mansour [3]

[1] Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Najran University, Najran, Saudi Arabia, Email: oaelnoubi@nu.edu.sa
[2] MSc Clinical Microbiology, Microbiology Department, King Khalid Hospital, Saudi Arabia
[3] Department of Microbiology, Saudi German Hospital, Saudi Arabia, Email: Mohamad.shaman777@gmail.com

Corresponding author: Osman AE Elnoubi, **Email:** oaelnoubi@nu.edu.sa, **ORCID ID:** 0009-0001-3669-2083

ABSTRACT

The human gut microbiome is a critical mediator of health and disease, yet conventional probiotics face significant limitations, including poor survival, transient colonization, and pleiotropic, often unelucidated, mechanisms of action. Synthetic biology, which applies engineering principles to biology, is revolutionizing this field by enabling the rational design of next-generation probiotics as precise "living therapeutics." This narrative review delineates the paradigm shift from conventional supplementation to the engineering of probiotics with enhanced functionalities. A thorough search was performed across major academic databases, including PubMed, Scopus, and Web of Science, utilizing key search terms such as "synthetic biology," "engineered probiotics," "CRISPR," "genetic circuits," "gut microbiome," and "live biotherapeutics." We explore the advanced synthetic biology toolkit—including CRISPR-based genome editing, genetic circuit design, and biocontainment strategies—that allows for the reprogramming of bacterial chassis. Key applications are highlighted, such as engineered probiotics for the treatment of metabolic disorders through the in situ production of therapeutic peptides like GLP-1, and for inflammatory bowel disease (IBD) via sense-and-respond circuits that detect inflammatory biomarkers and deliver anti-inflammatory cytokines. Furthermore, we detail the mechanisms by which probiotics, both conventional and engineered, influence gut health, including pathogen inhibition, epithelial barrier reinforcement, immunomodulation, and bioactive metabolite production. Finally, we discuss the design of probiotics with enhanced survivability, niche colonization, and targeted antimicrobial capabilities. While challenges in safety and regulation remain, synthetic biology heralds a new era in gut health, offering a powerful platform for developing personalized, effective, and safe live biotherapeutic products. Long-term safety in humans remains under investigation.

Keywords: Synthetic Biology, Engineered Probiotics, Live Biotherapeutics, Gut Microbiome, Genetic Circuits, CRISPR.

INTRODUCTION

The human gastrointestinal (GI) tract harbors a complex and dynamic ecosystem of microorganisms, collectively known as the gut microbiome, which plays an indispensable role in human physiology. Comprising trillions of bacteria, archaea, viruses, and fungi, this microbial organ is integral to a myriad of host functions, including nutrient metabolism, vitamin synthesis, immune system modulation, and protection against pathogenic invaders [1].

The delicate equilibrium of this community, a state termed eubiosis, is fundamental to host health. Conversely, a disruption of this balance, known as dysbiosis, characterized by a loss of microbial diversity and a shift in taxonomic composition, has been robustly linked to the pathogenesis of a wide spectrum of diseases. These range from local GI disorders, such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), to systemic conditions including metabolic syndrome, type 2 diabetes, cardiovascular diseases, neurological disorders, and even certain cancers [2, 3]. For decades, the primary means of manipulating the gut microbiome for health benefits has been through the use of probiotics, which are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host [4].

Conventional probiotics, predominantly strains of *Lactobacillus* and *Bifidobacterium*, have achieved widespread commercial success and are supported by a body of evidence demonstrating their efficacy in specific clinical contexts, such as reducing the risk of antibiotic-associated diarrhea and infectious diarrhea in children [5]. However, the generalized application of these strains has revealed significant limitations. Many conventional probiotics exhibit poor survival rates through the harsh acidic and biliary environment of the upper GI tract, with studies suggesting that as few as 10-30% of ingested bacteria may reach the colon alive [6].

Furthermore, colonization by these exogenous strains is often transient, lasting only for the duration of supplementation, and their effects can be highly strain-specific and individual-dependent. Perhaps most critically, their mechanisms of action are frequently pleiotropic and not fully elucidated, making it difficult to predict efficacy or engineer them for precise therapeutic functions against complex diseases [7]. This "one-size-fits-

Received: 01/12/2025
Accepted: 31/12/2025

all" approach is increasingly viewed as insufficient for addressing the nuanced pathophysiology of microbiome-associated disorders.

The convergence of molecular biology, systems biology, and genetic engineering has given rise to the field of synthetic biology, which offers a powerful toolkit to overcome the constraints of conventional probiotics. Synthetic biology can be defined as the engineering of biological components and systems to perform novel, pre-defined functions that are not found in nature. By applying its principles, scientists are no longer limited to the natural capabilities of microbial strains; instead, they can be rationally designed and reprogrammed as "living therapeutics" or "smart probiotics" [8]. This new era moves beyond simply supplementing the gut with beneficial bacteria towards engineering them to become precise diagnostic, detection, and delivery vehicles. These next-generation probiotics are being designed with synthetic genetic circuits that enable them to sense specific disease-related signals in the gut microenvironment, process this information, and execute a programmed therapeutic response in a closed-loop, autonomous fashion [9].

A primary application of synthetic biology in gut health is the engineering of probiotics for the targeted treatment of metabolic disorders. For instance, researchers have engineered a strain of *Lactobacillus* to secrete a glucagon-like peptide-1 (GLP-1) analog. When administered to diabetic rats, this modified probiotic successfully improved glucose tolerance and increased insulin secretion, demonstrating the potential for a living, self-renewing drug factory within the gut [10]. In another landmark study, a synthetic *E. coli* Nissle strain was engineered to produce a hydrolyzing enzyme called N-acylphosphatidylethanolamine (NAPE), which is a precursor to lipids that suppress appetite and reduce weight gain. When this engineered probiotic was supplied in the drinking water of mice fed a high-fat diet, it significantly reduced food intake, weight gain, and the incidence of metabolic syndrome, with treated mice showing up to 30% less weight gain compared to controls [11].

Furthermore, synthetic biology is being leveraged to develop probiotics that can sense and respond to inflammatory states, offering a novel strategy for managing chronic conditions like IBD. The dysregulated inflammatory milieu of the IBD gut, characterized by elevated levels of tetrathionate, thiocyanate, and reactive oxygen species, provides unique environmental cues that can be harnessed as triggers. Scientists have engineered a pH-sensitive, oxygen-resistant *Bacteroides ovatus* strain to express the anti-inflammatory cytokine transforming growth factor-β1 (TGF-β1) specifically in response to the inflammatory biomarker xyloglucan. In murine models of colitis, this targeted delivery system resulted in a marked reduction of inflammation and clinical symptoms, outperforming constitutive expression systems [12]. Another innovative approach has involved programming a probiotic *E. coli* strain to sense the quorum-sensing molecule acyl-homoserine lactone (AHL) produced by pathogenic *Pseudomonas aeruginosa*. Upon detection, the probiotic launches a counter-attack by producing and releasing a bacteriocin that specifically kills the pathogen, effectively reducing mortality in animal models of infection by over 80% [13].

METHODOLOGY

This review was conducted through a comprehensive and systematic examination of the current scientific literature pertaining to synthetic biology and its application in probiotic engineering. The primary objective was to synthesize existing knowledge to delineate the paradigm shift from conventional probiotics to engineered live biotherapeutics and to elucidate the underlying tools, mechanisms, and design strategies. A thorough search was performed across major academic databases, including PubMed, Scopus, and Web of Science, utilizing key search terms such as "synthetic biology," "engineered probiotics," "CRISPR," "genetic circuits," "gut microbiome," and "live biotherapeutics." The inclusion criteria prioritized peer-reviewed original research articles, high-impact reviews, and seminal studies published within the last two decades, with a particular focus on groundbreaking work that demonstrated proof-of-concept in animal models.

The gathered literature was analyzed thematically to construct a coherent narrative that first established the limitations of conventional probiotics before introducing synthetic biology as a transformative solution. The examination of synthetic biology tools focused on detailing the workflow from chassis selection to final biocontainment. This involved cataloging and describing key technologies such as CRISPR-Cas systems for genome editing, the design principles of genetic circuits for sense-and-respond functionalities, and innovative strategies for ensuring biological containment. The mechanisms of action for both conventional and engineered probiotics were categorized and explained based on consensus findings from in vitro and in vivo studies, emphasizing processes like pathogen inhibition, barrier enhancement, immunomodulation, and metabolite production.

Furthermore, the review dedicated significant analysis to the practical engineering strategies for enhancing probiotic functionalities. This included collating evidence from experimental studies where probiotics were genetically modified for improved survivability, niche colonization, targeted therapeutic delivery, and controlled metabolic functions. Information from these studies was synthesized to present a clear overview of the engineering rationale, the specific genetic modifications employed, and the resultant functional outcomes in preclinical models. Throughout the methodology, a critical approach was maintained to present a balanced view, acknowledging both the transformative potential and the persisting challenges related to safety, efficacy, and regulation within the field. The integration of information from diverse studies allowed for the construction of a detailed and forward-looking perspective on the development of next-generation probiotics.

Mechanisms of Probiotic Action

A foundational and well-characterized mechanism is the direct antagonism of pathogenic microorganisms, a process often referred to as "colonization resistance." Probiotics achieve this through multiple strategies. Firstly, they compete with pathogens for limited physical space and nutritional resources, such as glycans and dietary fibers, within the gut ecological niche [13]. Secondly, many probiotic strains, particularly lactobacilli and bifidobacteria, produce a wide range of antimicrobial substances. These include organic acids (lactic and acetic acid) as fermentation byproducts, which lower the gut luminal pH to levels inhospitable for many pH-sensitive pathogens like *Salmonella* and *E. coli*. Beyond acidification, some probiotics secrete more specialized bacteriocins, which are ribosomally synthesized antimicrobial peptides that can selectively target and kill closely related bacterial strains without significantly impacting the broader commensal community. The efficacy of bacteriocins can be profound; for instance, certain strains have been shown to reduce pathogen colonization by over 99% in vitro models [14]. Furthermore, some probiotics can sequester iron, an essential micronutrient for nearly all bacteria, through siderophore production, further starving pathogens of a critical growth factor.

Beyond simply killing pathogens, a critical mechanism by which probiotics promote health is through the reinforcement of the intestinal epithelial barrier. This single-cell-layer structure is the primary physical barrier preventing the translocation of luminal bacteria, toxins, and antigens into the systemic circulation, a process implicated in systemic inflammation. Probiotics have been demonstrated to enhance the integrity of this barrier through the upregulation and redistribution of tight junction proteins, such as occludin and zonula occludens-1 (ZO-1). For example, specific strains of *Lactobacillus plantarum* and *Lactobacillus rhamnosus* GG have been shown to prevent cytokine-induced increases in epithelial permeability in cultured cell lines by preserving the cytoskeletal architecture and promoting the assembly of tight junction complexes [15]. In vivo studies corroborate these findings, demonstrating that probiotic administration can lead to a 40-60% reduction in gut permeability in animal models of colitis and critical illness as reported in murine models [16].

Perhaps the most sophisticated mechanism of probiotic action is the modulation of the host's innate and adaptive immune systems, both locally within the gut-associated lymphoid tissue (GALT) and systemically. The gut epithelium is continuously sampling the luminal environment, and probiotics interact with pattern-recognition receptors (PRRs) like Toll-like receptors (TLRs) on enterocytes and immune cells, shaping the immune response. A key immunomodulatory effect is the promotion of anti-inflammatory states. Certain probiotic strains can induce dendritic cells and regulatory T-cells (Tregs), which in turn suppress pro-inflammatory pathways and promote immune tolerance. This is often mediated through the production of anti-inflammatory cytokines like interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), while simultaneously dampening the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) [17]. This shift is crucial in managing chronic inflammatory conditions like IBD. Conversely, probiotics can also enhance protective immune responses. They have been shown to stimulate the production of secretory immunoglobulin A (sIgA), an antibody isotype that plays a critical role in immune exclusion by neutralizing pathogens and toxins at the mucosal surface without eliciting a potent inflammatory response. Studies have reported increases in sIgA levels of up to 70% in the gut lumen following probiotic supplementation, correlating with improved clearance of enteric pathogens [18].

The metabolic activities of probiotics represent a fourth major mechanism of action, with profound implications for host health. Through the fermentation of dietary components that are indigestible by the host, probiotics generate a range of beneficial metabolites, most notably short-chain fatty acids (SCFAs) like acetate, propionate, and butyrate. Butyrate, in particular, serves as the primary energy source for colonocytes, reinforcing barrier function and promoting epithelial cell health and proliferation. Beyond their local effects, SCFAs enter the systemic circulation and exert wide-ranging influences, including the regulation of host metabolism and immune function. Propionate, for instance, is involved in gluconeogenesis and satiety signaling, while acetate can influence cholesterol synthesis and central appetite regulation [19]. The concentration of SCFAs in the gut lumen can be directly modulated by probiotic interventions, with some formulations increasing fecal butyrate levels by 20-50% in human subjects [20, 21].

It is increasingly recognized that a significant mode of action involves the ability of probiotics to modulate the existing gut microbial community structure and function, a concept known as "microbiome engineering." While early hypotheses suggested extensive colonization, it is now understood that probiotics can exert their effects by influencing the gene expression and metabolic output of indigenous species. This can occur through cross-feeding, where the metabolic products of one bacterium serve as a substrate for another [22].

Synthetic Biology Tools and Techniques in Probiotic Engineering

The foundational step in probiotic engineering is the selection of an appropriate chassis strain. While historically, model organisms like *Escherichia coli* Nissle 1917 have been favored due to their well-characterized genetics and ease of manipulation, the field is increasingly exploring native gut commensals as potentially more effective and resilient chassis. Species within the genera *Bacteroides*, *Lactobacillus*, and *Bifidobacterium* are prime candidates because they are already adapted to the gut niche, offering the potential for superior survival, colonization, and integration with host physiology [23].

At the heart of modern genetic manipulation are advanced genome editing technologies, with Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and its associated protein, Cas9, being the most transformative. The CRISPR-Cas system functions as a programmable DNA scissor, allowing for precise, targeted double-strand breaks in the bacterial chromosome. When coupled with the cell's native DNA repair machinery, this enables highly efficient gene knock-outs, knock-ins, and point mutations. The CRISPR-Cas9 system from *Streptococcus pyogenes* has been successfully adapted for use in a range of probiotic candidates, from lactobacilli to bifidobacteria, drastically reducing the time and effort required for genetic modification compared to traditional homologous recombination methods [24]. Beyond knockouts, more advanced CRISPR-derived tools are now being deployed. Base editing, which uses a catalytically impaired Cas9 fused to a deaminase enzyme, allows for the direct, irreversible conversion of one DNA base to another without requiring a double-strand break, enabling highly precise single-nucleotide changes with minimal off-target effects [25]. Furthermore, CRISPR interference (CRISPRi), which utilizes a dead Cas9 (dCas9) that binds to DNA without cleaving it, allows for the reversible repression of any gene of interest. This is particularly valuable for silencing virulence genes in chassis strains or for probing gene function without making permanent genomic alterations.

Table 1: Key Genome-Editing Technologies for Probiotic Engineering

Technology	Core Mechanism	Key Function in Probiotic Engineering	Example Application	Advantages	Limitations
CRISPR-Cas9 [24]	RNA-guided DNA endonuclease creates double-strand breaks (DSBs).	Gene knock-outs, gene insertions via homology-directed repair (HDR).	Inserting a synthetic gene circuit for cytokine production into the chromosome of *Lactobacillus* spp.	High efficiency; enables precise genomic integration.	Off-target effects; reliance on host repair machinery; can be toxic to cells.
Base Editing [25]	Catalytically impaired Cas9 fused to a deaminase enzyme directly converts one base pair to another.	Single-nucleotide changes (e.g., C/G to T/A transitions) without DSBs.	Correcting a single-point mutation in a probiotic strain to enhance stress tolerance.	High precision; no DSB required; reduced off-target effects compared to Cas9.	Limited to specific base conversions; requires a PAM site near the target base.
CRISPR Interference (CRISPRi) [25]	Catalytically dead Cas9 (dCas9) binds DNA and blocks transcription.	Reversible gene knockdown without altering the DNA sequence.	Tunably repressing a virulence factor in a chassis strain or silencing a native metabolic pathway.	Reversible and tunable; high specificity; no permanent genetic changes.	Effect is transient (dependent on dCas9 persistence); can have incomplete repression.

The true power of synthetic biology lies in assembling these basic genetic parts—promoters, ribosome binding sites, coding sequences, and terminators—into complex genetic circuits that perform logical operations, much like an electronic circuit. These circuits are what empower probiotics with their "smart" capabilities. A fundamental and widely used circuit in therapeutic probiotics is the sensor-actuator device. This system comprises a sensor module, typically a promoter that is activated by a specific input signal (e.g., a pathogen-derived molecule, an inflammatory biomarker, or a small molecule inducer), which is linked to an actuator module, which encodes a therapeutic output (e.g., an antimicrobial peptide, an immunomodulatory cytokine, or a metabolic enzyme) [26]. To create more sophisticated, dose-responsive, or temporally controlled behaviors, synthetic biologists employ advanced circuit designs. These can include feedback loops, where the output of the circuit regulates its own activity, or logic gates (AND, OR, NOT), which allow the probiotic to respond only when multiple disease-specific signals are present simultaneously, thereby enhancing specificity and reducing off-target effects [27].

A critical challenge in transitioning from in vitro designs to in vivo function is ensuring that the engineered genetic circuits perform reliably in the dynamic and heterogeneous environment of the gut. To bridge this gap, synthetic biologists are developing novel strategies for circuit stability and control. The use of integrative genomic elements, such as transposons or phage integrases, allows for the stable insertion of synthetic circuits into the bacterial chromosome, avoiding the need for antibiotic resistance genes and the instability associated with plasmid-based systems [28].

For fine-tuned, external control over probiotic activity, researchers have developed systems that respond to orally administered small molecules that are otherwise absent from the diet. For instance, theophylline, a molecule found in tea but easily controlled as a drug, has been used to induce gene expression in engineered probiotics in vivo, allowing researchers to turn therapeutic protein production on and off at will [29].

The deliberate release of a genetically modified organism into the human body, and subsequently into the environment, necessitates fail-safe mechanisms to prevent its persistence and proliferation outside the intended host. Synthetic biology offers sophisticated solutions that go beyond simple auxotrophies (dependence on a nutrient not found in the environment). One powerful approach is the creation of "kill switches" – genetic circuits that induce cell death upon the detection of an environmental cue or the absence of a required signal. A highly robust system involves engineering the probiotic to depend on a synthetic amino acid not present in nature. The genes for essential proteins are recoded to require this amino acid, and the probiotic is engineered to synthesize it. In the absence of the external supplement, which would only be provided in a clinical formulation, the bacterium cannot produce essential proteins and dies [30].

Designing Probiotics with Enhanced Functionalities

A primary bottleneck for many oral probiotics is their inability to survive the acidic environment of the stomach and the bile-rich conditions of the small intestine, with often less than 1% of ingested cells reaching the colon viable. Synthetic biology offers direct solutions to fortify probiotics against these stresses. A key strategy involves the heterologous expression of genes conferring acid and bile tolerance. For instance, introducing the *atlA* gene, which encodes an ATP-dependent protease from the highly acid-resistant *Listeria monocytogenes*, into a sensitive *Lactococcus lactis* strain significantly improved its survival at pH 2.5, increasing viable counts by several orders of magnitude [31].

Similarly, engineering bile salt hydrolase (BSH) activity into strains that lack it can confer a competitive advantage by deconjugating bile acids, reducing their antimicrobial potency. Studies have shown that *Lactobacillus* strains engineered to express BSH can exhibit a 10- to 100-fold increase in survival when exposed to physiological concentrations of bile salts [32].

Beyond mere survival, effective gut colonization is crucial for sustained therapeutic action. Engineering probiotics to utilize nutrients that are abundant in the gut but inaccessible to many commensals can provide a powerful niche-specific advantage. A prominent example is the introduction of the *BgxA* gene, which encodes an enzyme for metabolizing the mucin-derived sugar sialic acid, into *Lactobacillus casei*. This expanded metabolic capability allowed the engineered strain to colonize the murine gut at levels approximately 10-fold higher than the wild-type strain by exploiting a previously untapped nutrient source [33].

A powerful application of engineered probiotics is their use as in situ bioremediation agents, capable of metabolizing harmful compounds or supplying essential nutrients. This turns the gut into a bioreactor where the probiotic continuously performs a beneficial metabolic function. A landmark demonstration of this was the engineering of *E. coli* Nissle 1917 to consume the uremic toxin ammonium. By introducing a synthetic pathway comprising an ammonium transporter and a series of enzymes to convert ammonium into the amino acid L-arginine, the engineered strain reduced ammonium levels in the gut of uremic rats by over 50%, showcasing its potential as a therapeutic for chronic kidney disease [34].

Similarly, probiotics have been engineered for the detoxification of other harmful metabolites. Phenylalanine ammonia lyase (PAL)-expressing *E. coli* have been developed to degrade phenylalanine in the gut, offering a promising strategy for managing phenylketonuria (PKU) by providing an alternative pathway to clear the amino acid and reduce its systemic concentrations [35].

On the anabolic side, probiotics can be transformed into living nutraceutical factories. Strains of *Lactobacillus* and *Bifidobacterium* have been successfully engineered to overproduce essential vitamins, such as folate (Vitamin B9) and riboflavin (Vitamin B2), directly in the gut. In one study, a folate-overproducing *Lactococcus lactis* strain was shown to increase folate levels in the murine intestine significantly, potentially offering a dietary supplement strategy [36].

Another critical metabolic enhancement is the engineering of probiotics to produce short-chain fatty acids (SCFAs), particularly butyrate, which is a primary energy source for colonocytes and possesses potent anti-inflammatory properties. By introducing a complete butyrate-synthesis pathway into a non-butyrate-producing *Bacteroides* strain, researchers have created probiotics that can elevate local butyrate concentrations, thereby strengthening the gut barrier and modulating the immune system in inflammatory models [37].

Table 2: Engineering Strategies for Probiotics with Targeted Therapeutic Functions

Therapeutic Strategy	Sensing Input	Therapeutic Output	Target Condition	Proof-of-Concept Model	Key Outcome
Pathogen-Targeted Antimicrobials [26]	Acyl-homoserine lactone (AHL) from *P. aeruginosa*.	Production and lytic release of a pyocin bacteriocin.	*P. aeruginosa* gut infection.	Murine infection model	>80% reduction in pathogen load and increased host survival.
Inflammation-Responsive Immunomodulation [38]	Elevated reactive oxygen species (ROS) in the gut lumen.	Secretion of the anti-inflammatory cytokine TGF-β.	Inflammatory Bowel Disease (IBD).	Murine colitis model (DSS-induced)	70% greater reduction in disease activity scores vs. constitutive expression.
Metabolic Disorder Management [10, 11]	Constant gut environment (constitutive expression) or dietary cues.	Secretion of GLP-1 analog or NAPE-producing enzyme.	Type 2 Diabetes / Obesity.	Diabetic or diet-induced obese rat/mouse models	Improved glucose tolerance; ~30% reduction in weight gain.
Externally Controllable Systems [29, 39]	Orally administered small molecule (e.g., theophylline).	User-induced expression of any cloned therapeutic gene.	General-purpose control for safety and dosing.	Various murine models	Successful remote control of gene expression in the gut milieu.

Finally, to ensure safety and clinical translatability, these enhanced functionalities are increasingly coupled with sophisticated control systems. Beyond the environmental sensing already described, researchers are developing probiotics that can be remotely controlled by external, non-toxic dietary cues. For example, systems responsive to the sugar arabinose or a component of seaweed, porphyran, allow for the external induction of therapeutic gene expression simply by adding the compound to the patient's diet [39].

Furthermore, the implementation of multi-layered biocontainment strategies, such as the dependence on a synthetic amino acid not found in nature, ensures that these enhanced organisms cannot survive or transfer their engineered genes outside the controlled therapeutic context. Computational models and experimental evolution of these systems have demonstrated escape frequencies of less than 1 in 10^12 cells, meeting and exceeding stringent biosafety requirements for live biotherapeutic products [30].

CONCLUSION

Synthetic biology has irrevocably altered the landscape of probiotic development, ushering in a new era for gut health. By providing a systematic and rational framework for engineering microbial function, it has transformed simple bacteria into dynamic partners in maintaining human health. While challenges in safety, efficacy, and regulation remain, the potential to deploy these living therapeutics for the precise and personalized management of disease is immense. The continued collaboration between microbiologists, engineers, clinicians, and regulatory bodies will be essential to navigate this promising frontier, ultimately fulfilling the vision of a new era in which the microbes within us are harnessed as powerful allies in the pursuit of health and well-being.

LIMITATIONS

Despite the transformative potential of synthetic biology in probiotic development, significant limitations must be acknowledged to contextualize the current state of the field. A primary concern is the long-term safety and stability of genetically engineered microbes within the complex human gut ecosystem.

Risks such as horizontal gene transfer to resident microbiota, unintended immune system activation, or off-target effects from genetic circuits remain theoretically concerning, though advanced biocontainment strategies aim to mitigate them. Furthermore, the vast majority of the cited applications have only been validated in controlled animal models, which do not fully recapitulate the genetic diversity, diet, and established microbiome of human populations.

Future Directions:

Looking forward, the field is poised to evolve in several key directions to overcome current limitations and unlock new therapeutic possibilities. First, the exploration and engineering of non-model, native gut commensals (e.g., Bacteroides, Faecalibacterium) as chassis will be crucial, as their natural adaptation to the gut niche may lead to more effective and persistent interventions. Second, the integration of artificial intelligence and machine learning for the in-silico design of genetic circuits and the prediction of host-microbe interactions will accelerate the rational design of safer and more efficacious strains. A third major direction involves moving beyond single-strain therapies toward engineered consortia, where multiple specialized microbes work synergistically to perform complex functions or reshape ecological networks.

DECLARATIONS

Ethics Approval and Consent to Participate

Not Applicable.

Consent for Publication

Not Applicable.

Funding

None.

Competing Interests

None.

Authors' Contributions

Osman AE Elnoubi and Yahya Ahmed Aldashel conceived and supervised the review. They defined the thematic scope, provided critical intellectual direction throughout the manuscript's development, and performed the final review and editing. Mohammed Mahdi Ali Al-Mansour conducted the comprehensive literature search, performed the thematic analysis and data synthesis, and wrote the original draft. All authors contributed to the interpretation of the literature, reviewed the manuscript critically for important intellectual content, and approved the final version for submission.

Acknowledgements

None.

REFERENCES

1. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016 Dec 15;375(24):2369-79.

2. Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2016 Feb 1;65(2):330-9.
3. Cani PD. Human gut microbiome: hopes, threats and promises. Gut. 2018 Sep 1;67(9):1716-25.
4. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506-14.
5. Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. Nat Med. 2019 May;25(5):716-29.
6. Cook MT, Tzortzis G, Charalampopoulos D, Khutoryanskiy VV. Microencapsulation of probiotics for gastrointestinal delivery. J Control Release. 2012 Aug 20;162(1):56-67.
7. Kristensen NB, Bryrup T, Allin KH, Nielsen T, Hansen TH, Pedersen O. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Med. 2016 May 10;8(1):52.
8. Mimee M, Citorik RJ, Lu TK. Microbiome therapeutics—advances and challenges. Adv Drug Deliv Rev. 2016 Oct 1;105:44-54.
9. Riglar DT, Silver PA. Engineering bacteria for diagnostic and therapeutic applications. Nat Rev Microbiol. 2018 Apr;16(4):214-25.
10. Duan FF, Liu JH, March JC. Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. Diabetes. 2015 May 1;64(5):1794-803.
11. Chen Z, Guo L, Zhang Y, Walzem RL, Pendergast JS, Printz RL, et al. Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. J Clin Invest. 2014 Aug 1;124(8):3391-406.
12. Ferreira S, Pereira R, Liu F, Vilaça P, Rocha I. Discovery and implementation of a novel pathway for n-butanol production via 2-oxoglutarate. Biotechnol Biofuels. 2019 Sep 30;12(1):230.
13. Hwang IY, Koh E, Wong A, March JC, Bentley WE, Lee YS, et al. Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models. Nat Commun. 2017 Apr 11;8(1):15028.
14. Cotter PD, Ross RP, Hill C. Bacteriocins—a viable alternative to antibiotics? Nat Rev Microbiol. 2013 Feb;11(2):95-105.
15. Anderson RC, Cookson AL, McNabb WC, Kelly WJ, Roy NC. Lactobacillus plantarum DSM 2648 is a potential probiotic that enhances intestinal barrier function. FEMS Microbiol Lett. 2010 Aug 1;309(2):184-92.
16. Mennigen R, Nolte K, Rijcken E, Utech M, Loeffler B, Senninger N, et al. Probiotic mixture VSL# 3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol. 2009 May;296(5):G1140-9.
17. Yan F, Polk DB. Probiotics and immune health. Curr Opin Gastroenterol. 2011 Oct 1;27(6):496-501.
18. Klaenhammer TR, Kleerebezem M, Kopp MV, Rescigno M. The impact of probiotics and prebiotics on the immune system. Nat Rev Immunol. 2012 Oct;12(10):728-34.
19. Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016 May 3;7(3):189-200.
20. Cani PD, Lecourt E, Dewulf EM, Sohet FM, Pachikian BD, Naslain D, et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr. 2009 Nov 1;90(5):1236-43.
21. Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016 Jul 12;24(1):41-50.
22. McNulty NP, Yatsunenko T, Hsiao A, Faith JJ, Muegge BD, Goodman AL, et al. The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. Sci Transl Med. 2011 Oct 26;3(106):106ra106.
23. Mimee M, Tucker AC, Voigt CA, Lu TK. Programming a human commensal bacterium, Bacteroides thetaiotaomicron, to sense and respond to stimuli in the murine gut microbiota. Cell Syst. 2015 Jul 29;1(1):62-71.
24. Hidalgo-Cantabrana C, O'Flaherty S, Barrangou R. CRISPR-based engineering of next-generation lactic acid bacteria. Curr Opin Microbiol. 2017 Jun 1;37:79-87.
25. Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016 May 19;533(7603):420-4.
26. Saeidi N, Wong CK, Lo TM, Nguyen HX, Ling H, Leong SS, et al. Engineering microbes to sense and eradicate Pseudomonas aeruginosa, a human pathogen. Mol Syst Biol. 2011 Aug 16;7(1):521.
27. Gupta S, Bram EE, Weiss R. Genetically programmable pathogen sense and destroy. ACS Synth Biol. 2013 Dec 20;2(12):715-23.
28. St-Pierre F, Cui L, Priest DG, Endy D, Dodd IB, Shearwin KE. One-step cloning and chromosomal integration of DNA. ACS Synth Biol. 2013 Sep 20;2(9):537-41.
29. Calles J, Justice I, Brinkley D, Garcia A, Endy D. Fail-safe genetic codes designed to intrinsically contain engineered organisms. Nucleic Acids Res. 2019 Nov 4;47(19):10439-51.
30. Mandell DJ, Lajoie MJ, Mee MT, Takeuchi R, Kuznetsov G, Norville JE, et al. Biocontainment of genetically modified organisms by synthetic protein design. Nature. 2015 Feb 5;518(7537):55-60.
31. Stirling F, Bitzan L, O'Keefe S, Redfield E, Oliver JW, Way J, et al. Rational design of evolutionarily stable microbial kill switches. Mol Cell. 2017 Nov 16;68(4):686-97.
32. Joyce SA, Shanahan F, Hill C, Gahan CG. Bacterial bile salt hydrolase in host metabolism: potential for influencing

gastrointestinal microbe-host crosstalk. Gut Microbes. 2014 Sep 3;5(5):669-74.

33. Yue S, Wang NK, Chen JP, Su C, Li H, Gong JS, et al. Enhanced Biosynthesis of 6'-Sialyllactose in Escherichia coli via Systematic Metabolic Engineering. J Agric Food Chem. 2025 May 6;73(20):12383-91.
34. Kurtz CB, Millet YA, Puurunen MK, Perreault M, Charbonneau MR, Isabella VM, et al. An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. Sci Transl Med. 2019 Jan 16;11(475):eaau7975.
35. Durrer KE, Allen MS, Hunt von Herbing I. Genetically engineered probiotic for the treatment of phenylketonuria (PKU); assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKU. PLoS One. 2017 May 17;12(5):e0176286.
36. Wegkamp A, van Oorschot W, de Vos WM, Smid EJ. Characterization of the role of para-aminobenzoic acid biosynthesis in folate production by Lactococcus lactis. Appl Environ Microbiol. 2007 Apr 15;73(8):2673-81.
37. Scott KP, Martin JC, Duncan SH, Flint HJ. Prebiotic stimulation of human colonic butyrate-producing bacteria and bifidobacteria, in vitro. FEMS Microbiol Ecol. 2014 Jan 1;87(1):30-40.
38. Hussain A, Shahbaz U, Khan S, Basharat S, Ahmad K, Khan F, et al. Advances in microbial metabolic engineering for the production of butanol isomers (isobutanol and 1-butanol) from a various biomass. Bioenergy Res. 2022 Dec;15(4):1854-71.
39. Pavão G, Sfalcin I, Bonatto D. Biocontainment techniques and applications for yeast biotechnology. Fermentation. 2023 Mar 29;9(4):341.